All > Minnesota > Hepatocellular Carcinoma

Hepatic Artery Embolization for Liver Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mayo Clinic in Rochester, Rochester, MNLiver CancerHepatic Artery Embolization - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new way to give the imaging agent 68Ga-PSMA to better detect prostate-specific membrane antigen (PSMA) positive liver cancer.

Eligible Conditions
  • Liver Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
99mTc-based PSMA Imaging and Surgery Agent
1
Rest/ Stress imaging day 1
1
Catheterization

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to 2 years

Up to 2 years
Difference in PSMA uptake measured by SUVmax (fold change, absolute difference) in the kidneys, spleen and salivary glands between I.A. and I.V. PSMA PET.
Incidence of adverse events
Intraindividual intralesional difference in maximum standardized uptake value (SUVmax)
Intraindividual intralesional differences in tumor to background (TBR) of SUVmax

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
99mTc-based PSMA Imaging and Surgery Agent
1
Rest/ Stress imaging day 1
1
Catheterization

Trial Design

1 Treatment Group

Diagnostic (embolization, 68Ga-PSMA, PET/CT)
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Hepatic Artery Embolization · No Placebo Group · Phase < 1

Diagnostic (embolization, 68Ga-PSMA, PET/CT)Experimental Group · 3 Interventions: Gallium Ga 68 Gozetotide, Positron Emission Tomography and Computed Tomography Scan, Hepatic Artery Embolization · Intervention Types: Radiation, Procedure, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gallium Ga 68 Gozetotide
2016
Completed Phase 3
~2280
Positron Emission Tomography and Computed Tomography Scan
2015
N/A
~20

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years

Who is running the clinical trial?

Mayo ClinicLead Sponsor
2,960 Previous Clinical Trials
3,449,476 Total Patients Enrolled
4 Trials studying Liver Cancer
9,361 Patients Enrolled for Liver Cancer
National Cancer Institute (NCI)NIH
13,161 Previous Clinical Trials
41,167,373 Total Patients Enrolled
103 Trials studying Liver Cancer
21,268 Patients Enrolled for Liver Cancer
Scott M ThompsonPrincipal InvestigatorMayo Clinic in Rochester

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are scheduled to receive a medical procedure called hepatic artery embolization.
References

Frequently Asked Questions

What is the enrollment rate for this clinical study?

"Affirmative. Data hosted on clinicaltrials.gov attests that this medical research, which had its inception on February 11th 2022, is presently recruiting individuals to take part in the study. Specifically, 10 volunteers are required from a single location." - Anonymous Online Contributor

Unverified Answer

Are there still opportunities for patient involvement in this research?

"Current information on clinicaltrials.gov affirms that this research is actively recruiting individuals, having been initially posted February 11th 2022 and last updated March 22nd 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top